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Bone Morphogenetic Proteins -
New Hope in the Reconstruction
of Bone Defects in the
Stomatognathic Area
Summary
Bone morphogenetic proteins are a group of nine known proteins
which represent factors of growth and differentiation with the ability
of inducing new bone. Osteoinduction is a precisely defined sequence
of biological reactions which lead to the transformation of mesenchymal
cells into cartilage and bone.
In vitro and in vivo, studies have demonstrated that in order for
proteins to realise their clinical function they need carriers. So far ACS
(absorbable collagen sponge) has been most frequently used as a
carrier. However the search for the best carrier continues. Inves-
tigations carried out so far on experimental models (rats, dogs, mini
pigs and chimpanzees), and in human volunteers, have indicated the
great potential of BMP in the reconstruction of bone defects of the
stomatognathic area. Promising results have been obtained so far in
periodontal surgery, augmentation of alveolar ridges, augmentation of
the floor of the maxillary sinus, treatment of periimplantitis and
treatment of larger bone defects after extirpation of tumours.
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Introduction
Reconstruction and healing of large bone defects
continues to be the subject of study and investi-
gations of biomedical scientists throughout the
world. As long ago as 1668 the Dutch surgeon, Job
van Meekeren, described taking a calvary graft from
the skull of a dog for transplantation and repair of
defects in the skull bones of a soldier. In 1674 the
Dutch scientist, Antoni van Leeuwenhoek, one of
the inventors of the light microscope, described the
histological structure of bone. During the same
period Antonius de Hyde explained the formation of
callus over calcification of a blood clot on an
experimental frog model. In 1867 Ollier in Belgium
published a detailed paper on bone regeneration. In
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3. Xenogenous implants: implants transplanted
from an individual of a different species:
a) freeze dried calf bone
4. Alloplastic implants: implants of different mate-




So far the known materials, which are based
mainly HA (hydroxil-apatite), indicate the need 
for still better preparations, as the success of the
application of these preparations is relatively sat-
isfactory.
Significant advancement in understanding the
formation of bone, and also bone reconstruction and
healing, provided identification of a completely new
family of proteins, “bone morphogenetic proteins”
(BMP) (1). Duhamel was the first to explain the
problem of osteoinduction. However, it is con-
sidered that A.H. Redi from California University
was the main investigator and discoverer of mor-
phogenetic proteins. He confirmed their great
osteoinductive ability in in vitro studies and enabled
their clinical application in orthopedic surgery,
dental medicine, plastic and reconstructive surgery
(7,8).
Apart from the above preclinical and clinical
studies on animals, studies on humans were also
carried out in the USA. Thus current literature cites
the positive effect of BMP on the formation of new
kidney units (glomeruli) during application in a
diseased kidney, and also increased branching of
nerve cells treated with BMP (9,10).
Structure and classification of BMP (Bone
morphogenetic proteins)
Bone morphogenetic proteins (BMP) are a group
of nine currently known proteins (11,12). They
represent factors of growth and differentiation
isolated from bone with the possibility of induction
and regeneration of different species of muscu-
loskeletal tissues (bone, cartilage, tendons, liga-
ments, periodontium and dentine) and subgroups
are large groups of transforming growth factor 
(TGF - transforming growth factor) (13).
1820 a German, Philips von Walter, carried out the
first clinical autograft, and in 1880 a Scot, William
Macewen, produced the first clinical allograft. In
the United States Albee published a detailed review
of bone implants and the possibility of recon-
struction with them in 1915. In 1942, during the
Second World War, at a time when medicine was
crying out for reconstructive materials because of
war traumas, Inclan published a book on bone
banks. In this short historical review it is important
to mention that Taylor carried out the first fibula
graft in Australia, in 1975.
Reconstruction and healing of large bone defects
today continue to present a significant problem for
physicians, particularly surgeons, traumatologists,
orthopedists and maxillofacial and oral surgeons. In
the last 25 years treatment of deficiency of the loco-
motor and stomatognathic system had experienced
significant change and advancement. From the first
fibula graft to the present day much has been
achieved in the technique of vascularised bone trans-
plants, and bone tissue has consequently become one
of the most frequently transplanted human tissues
and is much more often used than skin, sheaths,
arteries and veins. One of the main reasons for this
is the fact that bone possesses an allogenous structure
and with this the possibility of formation of osteoin-
duction regardless of the survival of the bone tissue
which serves as an implant (1).
During the eighties, apart from bone transplants,
preparations on the basis of tricalcium phosphate
and hydroxilapatite were frequently used in recon-
structive bone surgery, which needed to have osteo-
conductive effect in the healing of bone defects
(2,3,4,5,6).
Such implants used in constructive surgery of
bone tissue can be classified as follows:
1. Autologous implants: implants which are trans-




c) combination of cortical bone and bone
marrow
2. Allogenous implants: implants transplanted from
one individual to another of the same species:
a) freeze dried cortical bone and bone mar-
row
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Proteins BMP-2 to BMP-9 have similar struc-
tural characteristics in contrast to BMP-1, which,
because of its sequence of ammoniacids cannot be
included in the TGF- super family, and neither is it
capable of inducing the formation of bone. Namely,
proteins BMP-2 to BMP-9 have the following
similar structural characteristics: hydrophobic secre-
tory major sequence, a large region of propeptides
and mature region-domain. This mature domain
contains active substance of a molecule; within the
domain there are seven cysteine remains which are
characteristic of the TGF - super family. BMP-8,
which contains the eighth cysteine in this region, is
an exception (14).
Molecular biology and mechanism of BMP
activity
Bone morphogenetic proteins are factors of
growth and differentiation isolated from bone with
the ability of regenerating damaged bone in post-
foetal life by repetition of cellular events that take
place in the formation of bone during embryonic
growth. It has been known for thirty years that bone
protein extracts enable regeneration of muscu-
loskeletal tissues in animal models (forming new
cartilage and bone tissue). This established the
specific biological activity of BMP, which is deter-
mined by the response of cells and microen-
vironment available at the site of the injury (15-19).
This process is known as enchondral ossifi-
cation, where new bone is not formed directly from
the mesenchyma by intramembranous ossification,
but that a cartilage intraphase occurs beforehand,
similar to that which occurs during foetal growth
and development. The primary activity of BMP is
differentiation of the mesenchymal precursor cells
to cells which form cartilage and bone (Fig. 1).
The mechanism of events which follow under
the influence of BMP is as follows: differentiation
of the mesenchyma, proliferation of mesenchymal
embrionic cells, chondrogenesis, hypertrophy and
mineralisation of the cartilage, angiogenesis and
vascular invasion, differentiation of osteoblasts and
finally osteogenesis (1). Nevertheless, when using
larger quantities of BMP it can be seen that
osteogenesis progresses at the same time as chon-
drogenesis (12,13).
It should be mentioned that BMPs are present in
various non-skeletal places during the period of
growth. This is demonstrated by their potential
extra-skeletal role, which has already been demon-
strated in preclinical experiments on animals (9,10).
Members of the group of the transforming factor
of growth - (TGF-ß) send signals from the cellular
membrane to the nucleus by means of specific type
I and type II receptors and Smad proteins (20).
Smad 1 and Smad 2 proteins are mediators of the
BMP signal, as Smad 2 and Smad 3 are conductors
of the TGF-ß signal. Smad 4 is the mutual mediator
for both paths. Smad 6 and 7 are inhibitors of the
signals of members of the group TGF-ß (17,20).
The bone matrix is one of the largest storages
of TGF-ß. Five isoforms is isolated from bovine
bone matrix, consisting of three homo-dimers and
two hetero-dimers. In human bone tissue TGF-ß1 is
the dominant izoforma of TGF-ß, depending on the
condition within the bone cells (21). TGF-ß is
situated within the bone cells as the inactive pre-
cursory complex in the latently connected forms
(proteinic). Activation of the latent form can be
started by means of tissue proteinase, changed pH
and osteoclastic resorption (21).
BMP osteoinduction
Bone possesses an allogenetic structure, and with
this the ability to create osteoinduction, regardless
of the survival of the bone tissue which served as
the implant. This is one of the main reasons why
bone tissue today is one of the most frequently
implanted human tissues.
Bone is a tissue which continually regenerates
throughout life, inducing morphogenetically formed
response, which remains its characteristic after birth.
Osteoinduction represents an accurate sequence of
biological reactions, which are very consistent and
which lead to the transformation of mesenchymal
cells into cartilage and bone, under the influence of
diffusive bone morphogenetic protein. After implan-
tation of decalcified bone matrix in an extra-skeletal
site, subcutaneously or intramuscularly, induction of
the implant causes cartilage and bone to develop in
the recipient. Cells that react to the stimulus of
morphogenetic protein are most probably undif-
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ferentiated mesenchymal cells of muscles and
muscular sheaths. Without morphogenetic protein
they do not have osteoinductive ability. BMPs have
so far been isolated from an organic matrix of
cortical bone from experimental animals, dentine
and enamel, and also osteosarcoma of man (1,22).
At the cellular level osteoinduction occurs in
three phases: chemotaxis, mitogenesis and differ-
entiation. It should be mentioned that optimal
induction in the formation of bone depends on the
joint activity of BMP and the complementary car-
rier, which is most important for future therapy
(12,23). As BMP is soluble in extracellular solution
it must have a carrier, without which it is phago-
cytized within ten days (12).
BMP carriers
The ideal carrier must be immunologically inert,
osteoconductive, resorptive, bioabsorptive, and
easily handled and modelled, in order to optimally
adapt to the site of application. Furthermore, it is
important for it to stimulate optimal osteogenic
activity with relatively small doses of rhBMP and
to assist angiogenesis, and finally vascularisation
(11). In 1996 Sigurdsson et al (24) examined the
following five materials as candidates for carriers:
1. Canine demineralized bone matrix - DBM)
2. Bovine crystal bone matrix (Bio-Oss) from
which the organic component has been
extracted.
3. ACS absorbable collagen sponge of bovine
collagen type I.
4. Poli (D, L-laktid-co-glikolid) micro particles
(PLGA).
5. Granules of poly-acrylic acid (Drilac).
However, none of the above carriers proved to
be ideal. DBM for example caused a large post-
operative swelling and increased bony mass com-
pared to the size prior to operation. The potential
transfer of infectious agents also restricts the use of
DBM.
Bio-Oss is a porous crystal bovine bone material,
from which the organic component has been
extracted. However, Bio-Oss resorbs slowly so that
after the relevant period necessary for the formation
of new bone, particles of unresorbed Bio-Oss
remained, resulting in a porous structure, i.e. poor
bone density. Slow resorption of the material can
restrict its use.
ACS is absorbable collagen sponge, obtained
from type I collagen, from bovine tendon. Post-
operative swelling moderate, handled very easily,
but not the ability to adequately retain the space.
PLGA showed poor mechanical characteristics
and inadequate clinical handling.
Drilac with blood also showed poor physical
integrity. Poor clinical handling and slow resorption
restrict its acceptability and usefulness as a carrier
(24).
Preclinical and clinical examination
The discovery of BMPs prompted their pre-
clinical and clinical examination. During the last
few years numerous experimental and clinical
investigations have been carried out of the
osteoinductive representatives of BMP, such as
rhBMP-7 (OP-1) and rhBMP-2. It has been
demonstrated in vivo that OP-1 (rhBMP-7) pos-
sesses the ability of inducing new bone formation
(17,17).
Studies on animals have shown that, apart from
OP-1, rhBMP-2 also possesses osteoinductive
ability, and that it has the key role in the growth and
regeneration of bone. 
Investigations carried out on several species of
mammals showed that both osteogen proteins cause
the formation of new bone (15-20). It can therefore
be said that OP-1, in combination with a produced
bone collagen carrier of high purity, can, by a single
local application, lead to renewal and regeneration
of bone defects on the long bones of dogs and
rabbits, but not human primates (e.g. in the African
green monkey a bone defect on the tibia, 2 cm in
diameter, healed within 20 weeks) (25).
Mechanical testing demonstrated that after four
weeks bone defects treated with OP-1 showed more
significant hardness than untreated after 12 weeks
(17). In the same way, a study on rats and small
pigs, with regard to mandibular augmentation and
reconstruction of mandibular discontinuity, showed
that OP-1 with Bio-Oss as the carrier, acts highly
osteoinductively (26).
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RhBMP-2 in combination with ACS (absorbable
collagen sponge) as the carrier, is also a surgically
safe and applicable implant for reconstruction of
different maxillofacial defects (27). In addition
rhBMP-2/ACS induced the formation of new bone
in all treated patients (sinuslifting), with no negative
complications, which was confirmed by histological
analysis, biopsy and CT (28).
Many scientists have investigated rhBMP-2 and
rhBMP-7/OP-1 on animal models, as possible peri-
odontal therapy (29-33). The object was to deter-
mine whether proteins induce the formation of
cement, periodontal ligament and regeneration of
alveolar bone. Animals used for the experiments
were monkeys, beagle dogs and rats.
Indications for the use of bmp in oral and
Maxillofacial surgery
Bone morphogenetic proteins can be applied for
bone defects of different etiology. Thus they can be
used for treatment of larger fractures and bone
defects as the result of trauma (blows, gunshot
wounds), after operative removal of malignant
processes, cysts, large ostitic processes and tumours.
They can also be applied in periodontology for
greatly compromised periodontal patients (29,30).
The main problem for periodontal therapy is
regeneration of the periodontium (29). Thus it is
necessary to induct osteogenesis and cemento-
genesis by the formation of new cement on the root
surface made bare by infectious-inflammatory dis-
ease, formation of bone and growth of functionally
orientated new fibres of connective tissue in the
bone and cement. 
Ideal regeneration requires newly formed bone,
new deposits of cement on the bare roots and growth
of functionally orientated new collagen fibres of the
periodontal ligament in new bone and cement.
Examples of today’s therapy for regeneration of
the periodontium include bone implants and guid-
ed tissue regeneration (GTR) technique. However,
as they are unsatisfactory, due to the fact that they
are clinically rather unpredictable, the need for the
development of new therapy remains. In this case
bone morphogenetic proteins could be the key
solution.
Morphogenetic protein enamel (EMDOGAIN-
BIORA AB) produced in Sweden, is today in
routine application in periodontology (31-37).
The results of studies on primates have shown
that proteins of enamel matrix, together with a
mucoperiosteal flap, lead to neogenesis of the peri-
odontal supportive tissue, which is identical to that
formed during the development of teeth. The newly
developed tissues are characterised by acellular
cement which lies firmly on the dentine, func-
tionally oriented periodontal ligament and new
alveolar bone. 
Investigations have also been carried out on
humans, the results of which were similar to those
obtained on primates (35,36,37). BMP is also
applied in the case of atrophic alveolar ridges and
augmentation of the sinus floor (sinus lifting),
enabling prosthetic care of the patient by the
construction of dental implants and the final fixed
or fixed-mobile prosthetic work.
They can also be used in the case of bone
dehiscience as a result of periimplantitis. The pos-
sibility of using BMP in wider indications for
apicectomy (periradicular ostitic changes) and for
the formation of dentine on still vital teeth cer-
tainly needs to be investigated on a human model.
Conclusion 
With the discovery of bone morphogenetical pro-
teins a new chapter has been opened in reconstruc-
tive maxillofacial and oral surgery, and also peri-
odontal surgery. Investigations carried out on pri-
mates, dogs and rats have demonstrated that osteoin-
ductive bone morphogenetic proteins rhBMP-2 and
rhBMP-7/OP-1 induce the formation of new bone.
With an adequate carrier these two osteoin-
ductive proteins enable the healing of bone defects
in the maxillofacial area. Successful fixed prosthetic
treatment by the construction of dental implants,
after lifting the floor of the sinus in partially or
totally edentulous patients, has become a definite
possibility with the use of BMP (38). Furthermore,
periodontally compromised patients, who had rel-
atively satisfactory results by previous therapy, are
today successfully treated with enamel morpho-
genetic proteins.
A S C Acta Stomatol Croat, Vol. 34, br. 3, 2000.324
Bone morphogenetic proteinsIrina FilipoviÊ-Zore et al.
It can be concluded that subsequent application
on humans has shown excellent results, and with
further investigation of the characteristics of pro-
teins and appropriate carriers, the future of therapy
with bone morphogenetic proteins is very prom-
ising. As Prof. S. VukiËeviÊ from Zagreb University
is one of the main investigators and inventors of
BMP, we hope that some of the indications for BMP
use in dental medicine, tested on an animal model,
will first be used on a human model in the School
of Dental Medicine in Zagreb.
